No. 24-5593

Otis Brandon v. Janssen Pharmaceuticals, et al.

Lower Court: Fourth Circuit
Docketed: 2024-09-20
Status: Denied
Type: IFP
IFP
Tags: drug-labeling fda-citations judicial-review medical-liability mental-capacity pharmaceutical-misconduct
Latest Conference: 2024-11-15
Question Presented (from Petition)

1) Did the lower courts fail to consider numerous ca.ses alleged
agianst the parmaceutical company Janssen and Johnson &
Johnson for misrepresentation, falsifying labels, etc?

2) Did the lower courts fail to consider the numerous cases
were the Federal Drug Administration cited the company Janssen
Pharmaceuticals and Johnson & Johnson for failure to inform
of the dangerous side effects of thier drug?

3) Did the lower courts follow a misinterpretation of judgement
passed by other Justices and other courts?

4) Did the lower courts fail to include in their decision same
/ similar issues decided in other cases? (see related cases)

5) Did the lower court follow a error of fact?

6) Didi the lower courts fail to take into account numerous
case were ruled against the defendants for allegations sighted
by plaintiff?

7) Did the lower courts fail to take into account the plaintiffs
"lack of Capacity" and Serious Mental Illness?

Question Presented (AI Summary)

Did the lower courts fail to properly consider evidence of pharmaceutical misconduct and misrepresentation in cases against Janssen and Johnson & Johnson?

Docket Entries

2024-11-18
Petition DENIED. Justice Alito took no part in the consideration or decision of this petition.
2024-10-31
DISTRIBUTED for Conference of 11/15/2024.
2024-07-11
Petition for a writ of certiorari and motion for leave to proceed in forma pauperis filed. (Response due October 21, 2024)

Attorneys

Otis Brandon
Otis Brandon — Petitioner